https://www.selleckchem.com/pr....oducts/compound-3i.h
The aim of this study was to evaluate the role of antiviral drugs in reducing the risk of developing severe illness in patients with moderate COVID-19 pneumonia. This retrospective cohort study included 403 adult patients with moderate COVID-19 pneumonia who were admitted to ShenzhenThird People's Hospital, China. The antiviral drugs arbidol, interferon alpha-1b, lopinavir-ritonavir and ribavirin were distributed to the patients for treatment. The primary endpoint of this study was the time to develop severe illness. Of the 462 pati
Like
Comment
Share
